ABIVAX to present at the prestigious Conference on Retroviruses and Opportunistic Infections (CROI) positive top-line clinical Phase IIa data for novel HIV drug-candidate ABX464
- Published on Thursday, 21 January 2016 17:00
Paris, France January 21st 2016 – ABIVAX (Euronext Paris: FR0012333284 – ABVX), an emerging leader in developing and commercializing novel antiviral therapies for diseases like HIV/AIDS and chronic Hepatitis B (CHB), today announced the acceptance of the abstract "Early Evidence of Antiviral Activity & Safety of ABX464 in HIV Treatment Naive Patients," as a late-breaking news presentation by the prestigious Conference on Retroviruses and Opportunistic Infections (CROI), t0 be held February 22-25, 2016 in Boston, Massachusetts, at the Hynes Convention Center.
+ 33 6 64 18 99 59 or
+ 33 1 44 54 36 65
Standard: +33 1 53 83 08 41